Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2023-10-12 Regulatory Filings
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'Press Release' and announces positive results from a Phase III clinical trial for a drug (Hexvix) being presented at a medical congress (SIU 2023). It details key findings, quotes the Chief Medical Officer, and provides context about the disease and the drug. This format—a formal announcement of recent operational/clinical news intended for immediate public dissemination—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change, and it focuses on clinical/operational news rather than just financial highlights, it fits best as a general announcement. Given the options, 'ER' (Earnings Release) is often used broadly for significant periodic announcements, but since this is purely clinical trial news, 'RNS' (Regulatory Filings - the fallback for miscellaneous announcements) is a strong candidate. However, in many financial databases, press releases announcing significant operational milestones or clinical data are often categorized under the closest equivalent to an 'Earnings Release' or a general 'Regulatory Filing'. Since it is a press release announcing a major milestone (Phase III results), and it is not a formal financial report, I will classify it as a general Regulatory Filing (RNS) as it is a broad announcement not covered by other specific codes like DIV, CAP, or MANG. It is not short enough to trigger the RPA rule, as it contains substantial detail.
2023-10-12 English
Photocure Partner Asieris to present first results for its Hexvix Phase III clinical trial in China at the SIU 2023 Annual Meeting
Regulatory Filings Classification · 99% confidence The document is explicitly titled 'Press Release' and announces that Photocure's partner, Asieris, will present first results from a Phase III clinical trial at the SIU 2023 Annual Meeting. This content—a timely announcement of clinical trial data presentation and partnership updates—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release detailing specific operational/clinical news rather than a formal financial statement (like 10-K or IR) or a general regulatory notice, 'ER' (Earnings Release) is the most appropriate fit, as press releases often accompany or precede formal earnings reports to disseminate key operational news. Given the content focuses on clinical trial results and presentation schedules, it is a form of operational news dissemination, which often falls under the ER category when it's a major update, or RNS if it were purely administrative. Since it contains significant operational news, ER is preferred over the general RNS fallback. The length (6095 chars) is substantial enough to be the primary document, not just a short announcement of a report.
2023-10-08 English
Photocure Partner Asieris to present first results for its Hexvix Phase III clinical trial in China at the SIU 2023 Annual Meeting
Earnings Release Classification · 95% confidence The document is explicitly labeled as a 'Press Release' dated October 7, 2023. It announces a future event (presentation of clinical trial results at the SIU 2023 Annual Meeting) and provides updates on a clinical trial milestone (reaching the primary endpoint in August 2023) and expected regulatory submissions (NDA in China). This content structure—a formal announcement of news, clinical progress, and partnership updates, issued outside of mandatory periodic financial filings (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release detailing operational and clinical progress, and not a formal financial statement or a transcript, 'ER' (Earnings Release) is the most appropriate fit, as these releases often contain key operational highlights even if they aren't strictly quarterly earnings announcements. Given the context of clinical trial updates, it functions as a significant corporate announcement. Q3 2023
2023-10-08 English
New Health Economic analysis in France concludes there is insignificant cost difference between White Light and Blue Light Cystoscopy use when applying ccAFU guidelines
Regulatory Filings Classification · 99% confidence The document is explicitly titled a "Press release" and announces the "publication" of a health economic analysis in a peer-reviewed journal. It details the findings of this analysis regarding Blue Light Cystoscopy (BLC) costs and outcomes in France. This format—a brief announcement summarizing research findings, often including context about the company and contact information—is characteristic of an Earnings Release (ER) or a general press announcement. Since the content is focused on a specific study result rather than periodic financial performance highlights (like revenue/EPS), and it is not a full report, transcript, or formal regulatory filing, it fits best as an Earnings Release (ER) if the company uses press releases for all major announcements, or potentially a Regulatory Filing (RNS) if it's a general announcement. Given the context of financial/economic analysis being released, ER is a strong candidate for a company communicating results, even if they are research results rather than quarterly financials. However, since it is a press release announcing the publication of a study, and not explicitly an earnings report, the most appropriate general category for a significant, non-standard announcement that isn't a core financial report is often RNS (Regulatory Filings/General Announcement). Upon review, the content is a scientific/economic update, not a standard earnings report (ER). It is a press release announcing a publication. If the company uses press releases for all material news, ER is plausible, but since it's not about quarterly financials, I will lean towards RNS as the best fit for a general, material announcement that doesn't fit other specific categories like DIV, CAP, or MANG. The document length (9312 chars) is substantial, suggesting it's more than just a brief notice, but it is still structured as a press release, not a full report (10-K, IR). I will classify it as an Earnings Release (ER) because companies often use this channel to disseminate significant, market-moving news, even if it's research-based, as it impacts future revenue potential.
2023-10-06 English
New Health Economic analysis in France concludes there is insignificant cost difference between White Light and Blue Light Cystoscopy use when applying ccAFU guidelines
Regulatory Filings Classification · 90% confidence The document is explicitly titled as a 'Press release' from Photocure ASA, dated October 6, 2023. It announces the publication of a 'New Health Economic analysis' in a peer-reviewed journal regarding the cost-effectiveness of Blue Light Cystoscopy (BLC) in France, referencing specific guidelines (ccAFU). This content structure—a news announcement summarizing research findings and providing context about the company and product—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific shareholder/management filing, and it serves to disseminate important, timely business/research news, it best fits the Earnings Release (ER) category, which often includes operational and research highlights outside of formal quarterly reports, or potentially a Regulatory Filing (RNS) if ER is too specific. Given the focus on a major research publication and its financial implications, ER is a strong candidate, but since it's not explicitly stating quarterly/periodical financial results (which is the core of ER), and it's a general announcement of a publication, it leans towards a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides. However, as a press release announcing a published study, it is most accurately classified as a general Regulatory Filing (RNS) as it doesn't fit the other specific categories well, although it contains elements of business updates. Given the options, RNS is the safest fallback for a press release announcing research findings that isn't a formal financial report or management change.
2023-10-06 English
Major shareholder disclosure in Photocure ASA
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "Standard form for notification of major holdings" and details changes in voting rights percentages (crossing thresholds from 5.58% to 4.93%) by a shareholder (Skandinaviska Enskilda Banken AB (publ)). This type of filing, which reports changes in significant share ownership that cross regulatory thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The structure and content align perfectly with regulatory requirements for disclosing major holdings.
2023-10-02 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.